Printer Friendly

ISIS PHARMACEUTICALS BEGINS PHASE II TRIALS ON ISIS 2105 FOR GENITAL WARTS

 CARLSBAD, Calif., Nov. 17 ~PRNewswire~ -- Isis Pharmaceuticals (NASDAQ: ISIP) today announced the start of its Phase II clinical trials on ISIS 2105, the company's antisense drug for treating genital warts. The trial will test whether ISIS 2105 can delay or prevent wart recurrence following surgical removal of the wart, and will be conducted as a double-blinded, placebo-controlled multi-center study. Patients participating in the new Isis study will first have their warts removed through standard surgical procedures. ISIS 2105 or placebo will then be administered into the wound margins at the time of surgery. In the future, Isis intends to begin trials of ISIS 2105 injected directly into intact warts without surgery.
 "To our knowledge, this new trial on ISIS 2105 is the first Phase II study to be carried out on an antisense oligonucleotide," said Daniel L. Kisner, M.D., executive vice president.
 Most genital warts are caused by two strains of the human papillomavirus (IIPV) which ISIS 2105 is designed to treat. IIPV is highly contagious, most commonly infecting individuals of both sexes under 45 years of age. It is estimated that genital warts are responsible for more than one million visits to physicians in the U.S. each year and that HPV is the fastest-spreading sexually transmitted disease of viral origin.
 Surgical removal is an effective method and common procedure for removing genital warts. However, recurrence of the wart at the site is common within only a few months. At present, there are no therapeutics that can effectively kill the virus and prevent recurrence. ISIS 2105 has the potential to do so because it is a specific antiviral agent targeted against HPV.
 ISIS 2015 was the first antisense drug to enter human clinical trials. Isis has completed its initial Phase I clinical trial in normal volunteers and found no evidence of unacceptable toxicity in the anticipated therapeutic dose range.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery, development and marketing of novel human therapeutic products based on proprietary oligonucleotides.
 -0- 11~17~92
 ~CONTACT: Daniel L. Kisner, M.D., of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, Ph.D., of Noonan~Russo Communications, 212-979-9180, for Isis Pharmaceuticals, Inc.~
 (ISIP)


CO: Isis Pharmaceuticals ST: California IN: MTC SU:

SM-OS -- NY020 -- 1709 11~17~92 09:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 17, 1992
Words:385
Previous Article:CONVEX COMPUTER CORP. AND SAS INSTITUTE JOIN FORCES TO DELIVER SAS SYSTEM ON SUPERCOMPUTERS
Next Article:HOLIDAY SHOPPERS HELP SUPPORT BIG BROTHERS/BIG SISTERS OF AMERICA IN NEW NATIONAL PROGRAM SPONSORED BY AMERICAN EXPRESS GIFT CHEQUES
Topics:


Related Articles
ISIS PUBLISHES NEW FINDINGS ON THE DESIGN OF ANTISENSE DRUGS
ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS
ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS
ISIS ANNOUNCES PHASE I CLINICAL TRIAL RESULTS ON ISIS 2105
ISIS PHARMACEUTICALS AWARDED NEARLY $1 MILLION IN FEDERALLY SPONSORED RESEARCH PROGRAMS
ISIS ANNOUNCES ANIMAL RESULTS FOR ADHESION MOLECULE INHIBITOR
ISIS PRESENTS DATA AT ICAAC FROM ANALYSIS CONFIRMING EFFICACY OF CMV RETINITIS ANTISENSE DRUG
ISIS ANNOUNCES RESULTS OF PILOT PHASE II CLINICAL TRIAL OF GENITAL WART COMPOUND AND DECISION NOT TO PURSUE FURTHER DEVELOPMENT
Isis Begins Pivotal Trial of Antisense Drug for Crohn's Disease

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters